Company

BioXcel Therapeutics, Inc.

Headquarters: New Haven, CT, United States

Employees: 89

CEO: Dr. Vimal D. Mehta Ph.D.

NASDAQ: BTAI -6.92%

Market Cap

$39.4 Million

USD as of July 1, 2024

Market Cap History

BioXcel Therapeutics, Inc. market capitalization over time

Evolution of BioXcel Therapeutics, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of BioXcel Therapeutics, Inc.

Detailed Description

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

BioXcel Therapeutics, Inc. has the following listings and related stock indices.


Stock: NASDAQ: BTAI wb_incandescent

Stock: FSX: BX2 wb_incandescent

Details

Headquarters:

555 Long Wharf Drive

12th Floor

New Haven, CT 06511

United States

Phone: 475 238 6837

Fax: 475 238 6837